Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 10/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13609513 | 0.86 | TSHR (0.41) | CA1CA2LCKPI4KBALDH1A1 | |
| SCHEMBL7424452 | 0.84 | LCK (0.44) | CA1CA2LCKPI4KBALDH1A1 | |
| SCHEMBL29556655 | 0.83 | GCK (0.52) | CA1CA2LCKPI4KBGCK | |
| SCHEMBL2174374 | 0.81 | LCK (0.52) | CA1CA2LCKPI4KBALDH1A1 | |
| SCHEMBL29579451 | 0.81 | CA1 (0.40) | CA1CA2LCKPI4KBGCK | |
| SCHEMBL9529240 | 0.79 | CA1 (0.41) | CA1CA2LCKPI4KBALDH1A1 | |
| SCHEMBL7691178 | 0.78 | LCK (0.47) | CA1CA2LCKPI4KBALDH1A1 | |
| SCHEMBL28889072 | 0.78 | ALDH1A1 (0.46) | LCKPI4KBALDH1A1HSD17B10MAPT | |
| SCHEMBL24434742 | 0.77 | CA1 (0.42) | CA1CA2LCKPI4KBALDH1A1 | |
| SCHEMBL24434747 | 0.77 | L3MBTL1 (0.47) | CA1CA2LCKPI4KBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281142-A1 | THIAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1921074-A1 | THIAZOLE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281142-A1 | THIAZOLE DERIVATIVE | GK, GCKR, AK2 | CA1 3121/4885CA2 463/4885LCK 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.